Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13531869 | 0.80 | HRH3 (0.53) | HRH3ATMESR1ESR2 | |
| SCHEMBL3400161 | 0.76 | HSP90AA1 (0.36) | HRH3HSP90AA1HSP90B1NPC1RAB9A | |
| SCHEMBL2247167 | 0.76 | RAB9A (0.37) | HRH3HSP90AA1HSP90B1NPC1RAB9A | |
| SCHEMBL720663 | 0.75 | HSP90AA1 (0.46) | HRH3HSP90AA1HSP90B1NPC1RAB9A | |
| SCHEMBL2248670 | 0.73 | ITGB3 (0.36) | HRH3HSP90AA1HSP90B1 | |
| SCHEMBL2246587 | 0.73 | USP1 (0.36) | HRH3HSP90AA1HSP90B1NPC1RAB9A | |
| SCHEMBL2181393 | 0.72 | ESR1 (0.41) | HRH3HSP90AA1NPC1RAB9AESR1 | |
| SCHEMBL2245827 | 0.71 | NPC1 (0.39) | HRH3NPC1RAB9AESR1ESR2 | |
| SCHEMBL3405712 | 0.71 | HSP90AA1 (0.41) | HSP90AA1HSP90B1 | |
| SCHEMBL2246205 | 0.69 | ESR1 (0.42) | HRH3NPC1RAB9AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | HRH3 665/4885HSP90AA1 1290/4885HSP90B1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.